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Abstract 
Previous studies suggest that membrane lipids may regulate proteolytic processing of 
the amyloid precursor protein (APP) to generate amyloid-beta peptide (Abeta). In the 
present study we have assessed the capacity for a series of structurally related 
synthetic ceramide analogues to modulate APP processing in vitro. The compounds 
tested are established glucosylceramide synthase (GS) inhibitors based on the D-1-
phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) structure. PDMP and 
related compounds PPMP and EtDO-P4 inhibited Abeta secretion from Chinese 
hamster ovary cells expressing human APP (CHO-APP) with approximate IC50 
values of 15, 5 and 1 microM, respectively. A trend for reduced secretion of the APP 
alpha-secretase product, sAPPalpha, was also observed in PDMP-treated cells but not 
in PPMP- or ETDO-P4-treated cells; whereas levels of the cellular beta-secretase 
product APP C-terminal fragment, CTFbeta, were increased by both PDMP and 
PPMP but unaltered with EtDO-P4 treatment. Our data also revealed that EtDO-P4 
inhibits endogenous Abeta production by human neurons. In conclusion, this study 
provides novel information regarding the regulation of APP processing by synthetic 
ceramide analogues and reveals that the most potent of these compounds is EtDO-P4. 
 
Keywords: Glycosphingolipid, sphingolipids, amyloid precursor protein, Alzheimer’s 
disease, neurodegeneration, amyloid-beta peptide 
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1 Introduction 
 
1.1 Role of amyloid-β peptide (Aβ) in Alzheimer’s disease (AD) 
 
A prominent feature of AD is the presence of amyloid plaques in brain regions 
associated with memory and learning. Amyloid plaques contain Aβ peptides as a 
major constituent and it is established that Aβ is derived from the amyloid precursor 
protein (APP) which undergoes two major pathways of enzymatic cleavage in the 
neuron [1]. The α-secretase pathway, which represents the major pathway for APP 
processing, does not generate Aβ as the metalloproteases (such as ADAM-10) 
responsible cleave in the middle of the Aβ sequence. In the second pathway, however, 
sequential cleavage of APP by β-secretase (BACE-1) and γ-secretase (a complex 
containing presenilins PS-1 or PS-2 as the catalytic sub-unit) generates Aβ peptide 
predominantly of 40 or 42 amino acids [2, 3]. Once formed, Aβ peptides may 
assemble as soluble oligomeric species that lead to protofibrils (Fig 1), which are 
neurotoxic at sub-micromolar concentrations [4, 5]. It is clear that different 
macromolecular forms of Aβ regulate inflammation, oxidative stress and lipid 
metabolism; all processes that are implicated in AD neurodegeneration [6-8]. In 
addition to factors that regulate the net production of Aβ in the brain, the ratio of 
Aβ1-40 to Aβ1-42 species generated, their propensity to form macromolecular 
complexes, and their clearance from the central nervous system (CNS) are all 
potential therapeutic targets for AD [2, 9]. Despite the recognised role for Aβ in AD 
neurodegeneration, the factors that modify Aβ production and deposition are not 
completely understood. 
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1.2 Glycosphingolipids (GSLs), Aβ and AD 
 
The brain is a rich source of GSLs that represent a large family of complex lipids 
derived from the sphingolipid biosynthetic pathway (Fig 2). The initial rate limiting 
enzyme for GSL synthesis is glucosylceramide synthase (GS), an enzyme that 
catalyses the conversion of ceramide to glucosylceramide (GlcCer). Through the 
action of glycosyl transferases, GlcCer may be further acted upon to form more 
complex GSLs that may contain sialic acid residues in which case the GSLs become 
negatively charged and are referred to as gangliosides (e.g. monosialylated 
gangliosides GM1, GM2, GM3). Non-sialylated “neutral” GSLs such as lactosyl 
ceramide (LacCer) and ceramide trihexoside (CTH) are also present in the brain [10]. 
 
More than 30 years ago it was reported that reductions in the levels of specific 
gangliosides were associated with AD; however, it was concluded that this was a 
“phenomenon accompanying extensive degradation of brain tissue rather than a factor 
in the aetiology of dementia” [11]. Similar studies performed almost a decade later 
also reported ganglioside reductions in AD brains and suggested this was due to 
“reduced density of nerve endings in the demented brains” [12]. These data suggest 
that the reduction of gangliosides observed in the AD brain may be a consequence of 
the disease rather than a cause. 
 
Subsequent in vitro and in vivo studies indicated that ganglioside (particularly GM1) 
administration could potentiate the trophic effects of nerve growth factor (NGF) and 
brain-derived neurotrophic factor (BDNF) [13-15]. Perhaps prematurely, these 
observations were set against the background data indicating “reduced” GSL levels in 
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AD brains and this led to the proposal that intracerebroventricular administration of 
GM1 could be used to treat AD [16, 17]. Overall this approach appeared to be 
unsuccessful as a treatment for AD and concerns were raised regarding 
immunological responses to GM1 administration [18-21]. 
 
Separate studies suggested that GM1 and other GSLs may in fact promote Aβ 
production and its assembly into neurotoxic complexes. It is known that GSLs are co-
localised with Aβ in amyloid plaques and it has been proposed that GM1 may interact 
with Aβ to form a seed for amyloid plaque formation [22, 23]. In addition, when GD3 
synthase gene knockout mice (phenotype characterised by reductions in the levels of 
several brain gangliosides) were crossed with APPswe+PSEN1DE9 amyloidogenic 
mice, both soluble Aβ and plaque load were reduced (85-95%) and this was 
associated with improved performance in cognitive tests [24]. Other recent studies 
have shown that GM1 also resolubilises mature Aβ fibrils to regenerate neurotoxic 
Aβ protofibrils from amyloid plaque [25]. Finally, in vitro studies indicate that GSLs 
may stimulate both BACE and γ-secretase activity to promote Aβ generation [26, 27]. 
 
Together these findings suggest that therapeutic intervention to reduce GSL synthesis 
may be worth investigating as a novel strategy to reduce Aβ-associated 
neurodegeneration in vivo. Related to this, the synthetic ceramide analogue D-1-
phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) is an established GSL 
synthesis inhibitor that has been shown to inhibit Aβ secretion from SH-SY5Y 
neuroblastoma cells [28]. Although PDMP is not suitable for long-term animal studies 
due to its high hepatic metabolism (plasma t1/2 ~1h), PDMP derivatives (Fig 3) 
including D-threo-1-phenyl-2-hexadecanoylamino-3-morpholino-1-propanol (PPMP) 
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and D-threo-ethylenedioxy-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol 
(EtDO-P4) may provide viable alternatives [29, 30]. EtDO-P4 in particular has been 
successfully used in long-term studies in mice [31, 32]. 
 
The aim of the present study was to investigate the impact that synthetic ceramide 
analogues PDMP, PPMP and EtDO-P4 have on APP processing and Aβ production 
using CHO cells that stably express human APP695. 
 
 
2 Materials and methods 
 
2.1 Materials 
 
Synthetic ceramide analogues D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-
propanol (PDMP), D-threo-1-phenyl-2-hexadecanoylamino-3-morpholino-1-propanol 
(D-PPMP) and L-threo-1-phenyl-2-hexadecanoylamino-3-morpholino-1-propanol (L-
PPMP) were purchased from Matreya (Pleasant Gap, PA, USA). D/L-threo-
ethylenedioxy-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol (D/L-EtDO-P4) 
was synthesised as described previously [30]. The D-EtDO-P4 enantiomer was 
purified by preparative normal phase HPLC using a Lux 5 µm Cellulose-2 AXIA 
packed chiral 250 x 21.2 mm column (Phenomenex, Lane Cove NSW, Australia). An 
Agilent 1100 HPLC system was used with a mobile phase 
hexane:isopropanol:diethylamine (85:15:0.1, vol:vol:vol), a flow rate of 10 ml /min 
and UV detection at 220 nm. D-EtDO-P4 eluted at 25 min and was collected from the 
column and dried under vacuum before use in experiments. Unless stated otherwise, 
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all synthetic ceramide analogues used were in the D-threo configuration. The γ-
secretase inhibitor N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl 
ester (DAPT) was purchased from Sigma (Castle Hill, NSW, Australia). Cell culture 
media and additives were obtained from Invitrogen (Melbourne, VIC, Australia) 
unless stated otherwise. Organic solvents were of analytical grade and were purchased 
from Ajax Finechem (Sydney, NSW, Australia). All other reagents were purchased 
through standard commercial suppliers.  
 
2.2 Cell culture 
 
The CHO cell line stably expressing the human 695-amino acid APP (CHO-APP) was 
generated and maintained as described previously [33]. This CHO cell model is an 
established method for analysis of APP metabolism [34-36]. CHO-APP cells were 
cultured in RPMI 1640 medium containing 10% fetal calf serum (FCS), 2 mM 
glutamine, 100 IU/ml penicillin, and 100 µg/ml streptomycin. The recombinant 
plasmid was maintained using puromycin (7.5 µg/ml). Cells were treated with 
synthetic ceramide analogues or DAPT as indicated for up to 48 h. These compounds 
were added to cells in complete growth medium containing 10% FCS. Human fetal 
brain tissues were obtained from 14 to 18 week-old fetuses collected after therapeutic 
termination following informed consent (ethical approval from the University of New 
South Wales Human Research Ethics Committee, HREC03187). Neurons were 
isolated from the brain tissues and cultured as previously described [37]. 
 
2.3 Western blotting 
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CHO-APP cells were routinely cultured in 12 well plates, rinsed with cold phosphate-
buffered saline (PBS) and lysed in lysis buffer (20 mM Tris–HCl, pH 7.5, 150 mM 
NaCl, 1 mM EDTA, 1% Nonidet P40, 0.5% deoxycholate, 0.1% SDS, and protease 
and phosphatase inhibitors). Bicinchoninic acid protein assays were performed on 
lysates and equal amounts of protein were separated on 12% SDS-PAGE gels and 
transferred onto 0.2 µm nitrocellulose membranes at 100 volts for 30 min. 
Membranes were blocked at 22˚C for 2 h in PBS containing 5% non-fat dry milk and 
probed with the relevant antibodies at 4˚C for 16 h to analyse APP (WO2 monoclonal 
1/400), APP plus APPβ C-terminal fragment (CTFβ, rabbit polyclonal 1/10000, 
Sigma, Cat No. A8717) and β-actin (rabbit polyclonal 1/2000, Sigma, Cat No. 
A5060). The membranes were washed three times in PBS containing 0.1% Tween-20 
and then incubated with horseradish peroxidase-conjugated goat anti-rabbit (Dako, 
1/2500) or rabbit anti-mouse (Dako, 1/2500) secondary antibody for 2 h. Signals were 
detected using enhanced chemiluminescence (ECL, Amersham Biosciences) and X-
ray films. Membranes were stripped and re-probed with β-actin antibody (rabbit 
polyclonal 1/5000, Sigma, Cat No. A5060) as a loading control. The signal intensity 
was quantified using NIH ImageJ software. 
 
Western blotting of secreted Aβ peptides and the secreted products of APP cleavage 
by α-secretase (sAPPα) was carried out as previously described [35]. Briefly, Aβ in 
the culture medium was separated on 12% SDS-PAGE gels and transferred onto 0.2 
µm nitrocellulose membranes at 65 volts for 17 min. Membranes were boiled in PBS 
for 5 min, probed with anti-APP WO2 monoclonal antibody followed by rabbit anti-
mouse horseradish peroxidase-conjugated secondary antibody and ECL detection 
applied as described above. Where indicated, the optical density of bands detected in 
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western blots was measured using NIH ImageJ software and the data regarding 
expression of APP and its proteolytic products presented as a ratio relative to non-
treated cells as previously described [35]. 
 
2.4 Cellular GSL analysis 
 
GSL profiles of CHO-APP cells were analyzed as described previously [38]. Briefly, 
cells grown to confluence in 6-well plates were treated with synthetic ceramide 
analogues as described above, rinsed three times with PBS and extracted in 2:1 (v/v) 
chloroform/methanol. The GSL fractions were isolated by silicic acid 
chromatography, and the glycan moiety was released by ceramide glycanase addition 
[39]. The GSL glycans were then fluorescently labeled and analyzed by normal phase 
HPLC as described previously [38]. Total peak area units for the glycan peaks were 
pooled to calculate the reduction of cellular GSL levels after treatment with ceramide 
analogues. Values were expressed as a percentage of total GSL levels present in 
vehicle-treated CHO-APP cells. 
 
2.5 Cell viability assay 
 
CHO-APP cells were seeded in 96 well plates at 80% confluence. Cells were treated 
with the indicated doses of ceramide analogues for 48 hours. Culture media was 
removed and 100 µl of media (DMEM, 10% FCS) containing 0.5 mg/ml 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Catalog no. M2128, 
Sigma), was added and the cells incubated for 1 h at 37˚C. Media was discarded and 
the cells dissolved in DMSO (100 µl /well) and the absorbance of the cell lysates was 
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measured at 550 nm. Higher absorbance values indicate increased cell viability. Cell 
number and morphology was also assessed by direct counting of cells in 5 randomly 
selected fields in each of 3 triplicate wells. The cells remaining attached were 
captured in digital images recorded under phase contrast (20 X) and the printed 
images were used for cell counting. 
 
2.6 Statistical Analysis 
 
Unless stated otherwise, experiments were performed in triplicate and repeated at 
least three times. Data are presented as means with S.E. shown by error bars. 
Differences were considered significant where P < 0.05 as determined by the 2-tailed 
Student’s t-test for unpaired data. 
 
 
3 Results 
 
3.1 Regulation of Aβ production by ceramide analogues 
 
A previous study reported that PDMP could inhibit the secretion of Aβ from SH-
SY5Y neuroblastoma cells [28]. Our initial experiments aimed to examine the impact 
that two derivatives of PDMP (PPMP and EtDO-P4), that have more potent GS 
inhibitory activity than PDMP [30], might have on cellular Aβ secretion. Our data 
indicate that both PPMP and EtDO-P4 inhibit Aβ secretion from CHO-APP cells. 
Using a 48 h treatment period, we found that the IC50 values for the inhibition of Aβ 
secretion by PDMP, PPMP and EtDO-P4 were 15.8 µM, 5.8 µM and 1.0 µM, 
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respectively (Fig 4). The reduction in extracellular Aβ levels induced by these 
compounds (when used at values that are close to their IC50 values) is illustrated by 
the western blots shown in Figure 5. Similar to the previous studies with SH-SY5Y 
cells [28], we noted a trend for PDMP to also inhibit the secretion of sAPPα from 
CHO-APP cells (Fig 5); although overall this did not reach statistical significance (P 
= 0.051). There were no obvious changes in sAPPα secretion when cells were treated 
with either PPMP or EtDO-P4 at concentrations that reduced Aβ secretion by ~50% 
(Fig 5). Full-length cellular APP levels were significantly increased by ~ 20% with 
PPMP treatment whereas a non-significant trend for increased cellular APP was 
observed with EtDO-P4 treatment (Fig 5). These data suggest that there may be subtle 
differences in the mechanisms by which these structurally-related ceramide analogues 
modulate APP processing and Aβ secretion. Intracellular Aβ was not detectable in 
CHO-APP cells either with or without ceramide analogue treatment (data not shown). 
The fact that Aβ is very efficiently secreted by the CHO-APP cells is consistent with 
previous studies [33, 35, 36]. 
 
3.2 Toxicity profiles of ceramide analogues 
 
EtDO-P4 is a potent GS inhibitor that has already been used in long-term mouse 
studies [31, 32]. However, because these ceramide analogues may also exhibit 
cytotoxicity, especially towards cancer cell lines [40, 41], we also compared their 
affect on cellular MTT reduction as a marker of cytotoxic potential. Significant 
decreases in cellular MTT reduction were detected for all three ceramide analogues 
when tested at concentrations that inhibit Aβ secretion by ~50% (Fig 6). The MTT 
reduction assay is reliable method for detection of cell death, however, it may also 
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detect changes in mitochondrial electron transport, cellular metabolic activity and 
cellular stress well in advance of cell death; particularly under conditions where cells 
are exposed to Aβ [42, 43]. Therefore cell survival was also checked by anlaysing 
phase contrast images of CHO-APP cells as described in the Methods section. Gross 
morphological changes and overt cytotoxicity were only observed when the 
compounds were used at concentrations ~ 2-fold greater than their IC50 values for Aβ 
secretion. As an example, phase contrast images of CHO-APP cells treated with up to 
5 µM EtDO-P4 for 48 reveal significant loss of the cell monolayer and a clearly 
“rounded-up” cellular morphology (Fig 6). Overall, however, these data indicate that 
the cytotoxicity of these ceramide analogues is reasonably low when used at 
concentrations that inhibit Aβ secretion by ~50%. 
 
3.3 Impact of ceramide analogues on APP CTFβ generation 
 
In order to better understand how PDMP, PPMP and EtDO-P4 may be inhibiting 
cellular Aβ secretion, we also assessed the formation of the APP CTFβ fragment 
using a specific antibody that recognises the APP C-terminal amino acids 676-695. 
Increased cellular CTFβ levels in association with reduced Aβ secretion are 
associated with inhibition of γ-secretase activity. Our data indicate that PDMP and 
PPMP when used at their ~IC50 concentrations both caused a marked 6- to 12-fold 
increase in cellular CTFβ (Fig 7). In contrast, EtDO-P4 induced only a moderate 20% 
increase in CTFβ levels (Fig 7). The γ-secretase inhibitor DAPT was used as a 
positive control in these experiments and was found to increase CTFβ levels by 50-
fold and reduce Aβ secretion to undetectable levels (Fig 7). We also assessed the 
activity of the L enantiomer of PPMP, which does not inhibit GS activity. L-PPMP 
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had no significant impact on either cellular CTFβ levels or on Aβ secretion (Fig 7). 
These data indicate that although the inhibition of Aβ secretion that is induced by 
PDMP and PPMP is associated with increased CTFβ accumulation (and thus 
presumably γ-secretase inhibition), EtDO-P4 may have a different anti-amyloidogenic 
mechanism of action. Furthermore, since L-PPMP did not have an impact on either 
CTFβ or Aβ levels, this suggested that direct inhibition of GS activity may be 
required for the anti-amyloidogenic activity of these ceramide analogues. One 
possible caveat with the data related to L-PPMP is that a previous study has indicated 
that when used at low µM concentrations it may stimulate sphingolipid synthesis 
(assessed after 48 h treatment of Colo-205 cells) and thereby introduce an non-
controlled confounding variable in the present study [44]. 
 
3.4 Impact of EtDO-P4 on secretion of endogenous Aβ from primary human 
neurons 
 
The data above indicate that EtDO-P4 is a potent inhibitor of cellular Aβ secretion 
that the mechanism for this ceramide analogue is associated with only a moderate 
CTFβ accumulation. In order to assess whether this action of EtDO-P4 may also be 
relevant to endogenously synthesised Aβ, we also treated primary human neurons 
with EtDO-P4. Similar to the results derived from the CHO-APP cell experiments, 
EtDO-P4 also inhibited Aβ production by human neurons (Fig 8). In this case the IC50 
for Aβ secretion was found to be ~ 3 µM and, under these conditions, total cellular 
GSL levels were reduced by ~ 50% (Fig 8). 
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4 Discussion 
 
Increasing evidence suggests that there may be a link between dysregulation of 
cerebral lipid homeostasis and AD. For example, there is data indicating that synaptic 
terminals and isolated lipid raft fractions from AD brains are enriched in cholesterol 
and specific GSLs, respectively [45, 46]. While causation has not been proved, it has 
been speculated that such changes in membrane lipid composition could contribute to 
the acceleration of Aβ deposition in AD [45-47]. If increased neuronal GSL and 
cholesterol levels do increase Aβ formation in vivo then it would be predicted that in 
genetic diseases resulting in the accumulation of these lipids in the brain, an increase 
in APP processing to produce Aβ would be observed. While this idea has not been 
extensively examined, studies in human Niemann-Pick Type C (NPC) brains and 
NPC mice (in which cholesterol and GSLs accumulate due to defects in endocytic 
trafficking) do indicate that even though amyloid plaques are not a feature of NPC, 
Aβ production is significantly increased and it is thought that this may contribute to 
NPC neurodegeneration [48-50]. 
 
There are potentially several mechanisms to explain how GSLs may impact on APP 
processing, amyloid deposition and Aβ neurotoxicity. It is clear that the 
amyloidogenic processing of APP by β- and γ-secretases occurs within cell 
membranes in lipid raft microdomains that are enriched with GSLs and cholesterol 
(Fig 1) [47, 51-55]. Importantly, even subtle increases in the amount of raft lipids 
(including GSLs and cholesterol) in the cell membrane enhance APP processing to 
generate Aβ and there may be multiple mechanistic explanations for this. These 
include an increase in the proportion of APP and β-secretase (BACE) localised to 
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lipid rafts, and direct modulation of BACE proteolytic activity [26, 56]. There is also 
data derived from purified γ-secretase complex reconstituted in phosphatidylcholine 
(PC) liposomes that indicates strong induction of γ-secretase activity upon inclusion 
of porcine brain gangliosides to account for from 5% to 25% of the total liposome 
lipid (whereas increasing the ganglioside content to 50% or above inhibited γ-
secretase activity) [27]. 
 
In addition there may be direct interaction of cholesterol and GSLs in the membrane 
that together have an impact on APP processing. Related to the present experiments, 
our previous research showed that enrichment of cells with GSL promoted membrane 
cholesterol accumulation and that the PDMP potently stimulated cellular cholesterol 
efflux via an ABCA1 transporter-dependent pathway [38]. We also showed that 
PDMP treatment (10µM for 72h) not only reduced cellular GSL expression but also 
led to a depletion of cholesterol from Triton X-100 insoluble membrane 
microdomains [38]. A subsequent study showed that 25 µM PDMP inhibited Aβ 
secretion from SH-SY5Y neuroblastoma cells by ~50% over 48h [28]. These studies 
led us to examine PDMP-related ceramide analogues that maybe used to test for 
possible anti-amyloidogenic activity in future studies of amyloidogenic transgenic 
mice. 
 
The aim of the present study was therefore to examine the potential for synthetic 
ceramide analogues to inhibit Aβ secretion in vitro. We showed that PDMP and 
related compounds PPMP and EtDO-P4 inhibited Aβ secretion from CHO-APP cells 
with IC50 values of 15.8 µM, 5.8 µM and 1.0 µM, respectively. For reasons that 
remain to be defined, there were no universal effects of the different compounds on 
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the levels of full length APP or APP proteolytic products sAPPα and cellular CTFβ. 
Based on the IC50 values and the inactivity of L-PPMP, we speculate that the 
mechanism by which these ceramide analogues inhibited Aβ may be related to their 
inhibition of GS activity, however, further experiments are clearly required to identify 
the precise pathways involved. It has been suggested that changes in cellular ceramide 
and diglyceride levels may correlate better than GS inhibitory activity with the 
cytostatic effects of ceramide analogues [40]. Whether differential changes in 
ceramide and diglyceride homeostasis also contribute to the different effects we have 
observed using synthetic ceramide analogues and their capacity to modulate different 
aspects of APP processing remains to be determined. 
 
Regardless, of the remaining details regarding the anti-amyloidogenic mechanism of 
action, the fact that EtDO-P4 inhibits Aβ secretion from both CHO-APP cells and 
human neurons at low µM concentrations and is applicable to in vivo mouse studies, 
indicates further investigation of this compound in an experimental animal model of 
AD is worth pursuing. Due to the rapid hepatic metabolism of PDMP (plasma t1/2 
~1h) this compound is not suitable for long-term animal studies. However, EtDO-P4 
is ideal for in vivo studies with a t½ in mice of ~7h and our own data indicating i.p. 
injection of apoE-/- mice with EtDO-P4 (10 mg/kg) 3 times per week for 4 months is 
well tolerated and results in 49% inhibition in plasma GSL levels [32]. 
 
EtDO-P4 has a reported IC50 for GS (Fig 2) of 100 nM and at levels 100-fold higher 
than its IC50 for GS has no impact on ceramide, sphingomyelin, phospholipid or 
cholesterol synthesis [30, 31]. EtDO-P4 is a hydrophobic molecule that appears to 
cross the blood brain barrier (BBB) and has been shown to reduce GlcCer levels in 
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the brains of Fabry disease (a GSL storage disease) mice by 16% when administered 
at 10 mg/kg as a complex with phospholipid vesicles (PLV) [31]. The transport of 
EtDO-P4 across the blood brain barrier is consistent with several earlier short term 
(few days to 2 weeks) studies that have used the less potent PDMP analogues to 
modulate cerebral GSL metabolism in rats, gerbils and mice [29, 57-59]. In these 
“acute” studies, doses of 20 to 40 mg/kg administered i.p. twice per day (using 
detergent Tween 80 as vehicle) were used. One of these latter studies [29] revealed 
that a peak brain concentration of 50 µM for D-PDMP was achieved 30 min after a 
single i.p. injection of 80 mg/kg after which the brain concentration dropped to 6 µM 
at 3h and plateaued resulting in 4 µM PDMP detected in the brain at the 8h (final) 
time point. Considering the development of human therapeutics, it is potentially 
relevant that a GS inhibitor (Genz-112638) is currently in Phase II clinical trials 
(http://clinicaltrials.gov/show/NCT00358150) to treat Type 1 Gaucher disease, and it 
may be the case that this compound can also modulate neuronal Aβ secretion; 
although we are not aware of any study in which this has been assessed. 
 
5 Conclusion 
 
In conclusion, our current study provides novel information regarding the regulation 
of APP processing by synthetic ceramide analogues and reveals that the most potent 
of these compounds, EtDO-P4, may regulate APP processing through inhibition of 
GS. Future studies of the potential impact that EtDO-P4 or related compounds have 
on Aβ homeostasis in amyloidogenic mouse models appear to be worth pursuing. 
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Figure legends 
 
Figure 1. Schematic representation of amyloid precursor protein (APP) processing. 
Amyloidogenic processing by β-secretase and γ-secretase generates Aβ peptides in 
the cholesterol- and GSL-enriched lipid raft microdomains within cell membranes. 
Non-amyloidogenic processing by α-secretase occurs predominantly in non-raft 
microdomains. Abbreviations are explained in the text. 
 
Figure 2. Simplified scheme of sphingolipid biosynthesis. PDMP, PPMP and EtDO-
P4 inhibit glucosylceramide synthase (GS) which catalyses the first step in 
glycosphingolipid synthesis. (S1P, sphingosine-1-phosphate; C1P, ceramide-1-
phosphate; other abbreviations are explained in the text). 
 
Figure 3. Chemical structures of synthetic ceramide analogues used in this study. 
 
Figure 4. Determination of IC50 values for inhibition of Aβ production by synthetic 
ceramide analogues. CHO-APP cells were treated with the concentrations PDMP (A), 
PPMP (B) or EtDO-P4 (C) indicated for 48 h and Aβ in the culture medium was 
measured by western blotting. Optical density measurements of the western blots 
were used to quantify Aβ. Data are derived from 4, 9 and 9 experiments for PDMP, 
PPMP and EtDO-P4, respectively. Data are mean values with error bars indicating 
SE. 
 
Figure 5. Impact of synthetic ceramide analogues on sAPPα and Aβ production. 
CHO-APP cells were treated with 15 µM PDMP (A), 5 µM PPMP (B) or 1 µM 
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EtDO-P4 (C) for 48 h and cellular APP and secreted sAPPα and Aβ were measured 
by western blotting. β-actin was used as a loading control. (D) Optical density 
measurements of the western blots, control (grey bars) and treated (black bars). The 
bars in the histograms represent (from L to R) levels of APP, sAPPα and Aβ for each 
analogue tested. Data are mean values with error bars indicating SE, *p< 0.05, 
***p<0.001. 
 
Figure 6. Cytotoxicity assay of synthetic ceramide analogues. CHO-APP cells were 
treated with PDMP (A), PPMP (B) and EtDO-P4 (C) for 48 h and cytotoxicity was 
measured using the MTT assay as described in Materials and Methods. Data are mean 
values (n=3) with error bars indicating SE, *p< 0.05, ***p<0.001. Phase-contrast 
microscopy of CHO-APP cells treated with EtDO-P4 at 0 µM (D), 0.1 µM (E), 
0.5 µM (F), 1 µM (G) or 5 µM (H) for 48 h. 
 
Figure 7. Effect of synthetic ceramide analogues on the intracellular processing of 
APP. CHO-APP cells were treated with 15 µM PDMP or DAPT (positive control, 
1µM) (A), 5 µM L-PPMP or 5 µM D-PPMP (B) or 1 µM EtDO-P4 (C) for 48 h and 
cellular APP and CTFβ and secreted Aβ were measured by western blotting. β-actin 
was used as a loading control. (D–F) Optical density measurements of the western 
blots, respectively, control (grey bars) and treated (black bars). Data are mean values 
with error bars indicating SE, *p< 0.05, ***p<0.001. C, control; PD, PDMP; DA, 
DAPT; L-P, L-PPMP; D-P, D-PPMP; P4, EtDO-P4. 
 
Figure 8. Effect of EtDO-P4 on Aβ and glycosphingolipid levels in primary human 
neurons. Human neurons were treated with 3 µM EtDO-P4 for 48 h and (A) secreted 
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Aβ was measured by western blotting and, (B) cellular glycosphingolipid (GSL) by 
HPLC, control (grey bars) and EtDO-P4 (black bars). Data are mean values (n=3) 
with error bars indicating SE, **p<0.01, ***p<0.001. 
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